Headquartered in Manhattan and often framed as a beacon of American scientific ingenuity, Pfizer presents itself as a research-driven, health-focused multinational. Yet its financial disclosures tell a parallel story—one not of clinical trials or vaccines, but of transfer pricing arrangements, intellectual property domiciling, and tax structuring on a global scale.
This is not tax evasion. It is tax avoidance, by design.
A tale of two profit centres
Between 2014 and 2024, Pfizer reported $132.4 billion in pre-tax profit. Yet only $21.4 billion of that appeared in its US operations. The remaining $110,694. billion—over 86 per cent—was recorded in foreign subsidiaries.
While the US is Pfizer’s largest market by revenue, it has not been its main profit centre. In several years, US operations produced accounting losses, while foreign affiliates reported substantial gains. In 2021, the company posted $6.1 billion in domestic profit, but nearly three times that—$18.2 billion—abroad. In 2023, the pattern reached an extreme: global pre-tax income stood at just $1.1 billion, but the group received $1.1 billion in net tax benefits, producing a negative effective tax rate.
In 2024, Pfizer reported a profit before tax (PBT) of $8,023 billion, yet its profit after tax (PAT) is higher at 8,051. This only makes sense if the income tax expense is actually a negative expense—in other words, a tax benefit rather than a tax payment. This can occur due to factors like deferred tax assets, R&D tax credits, or prior-year overprovisions that result in a net tax refund.
Intellectual property as a tax asset
Pfizer’s tax efficiency hinges on where it books profits—and that, in turn, depends on where it houses intellectual property. While many of its medicines are researched and developed in the United States, the company locates ownership of the resulting IP in lower-tax jurisdictions such as Ireland.
These offshore entities then license the IP back to Pfizer affiliates worldwide, collecting royalties. The costs of these royalties reduce taxable income in higher-tax countries like the US, while the royalty income accrues in jurisdictions where the corporate tax rate is far lower.
The Irish structure
Ireland plays a pivotal role in Pfizer’s global tax model. The company operates more than 25 subsidiaries in the country, most of which are unlimited liability companies. This legal form exempts them from public disclosure of financial accounts.
Among them are Pfizer Ireland Pharmaceuticals Unlimited Company, Pfizer Export Company Unlimited Company, and Biohaven Pharmaceutical Ireland DAC—a firm that booked $451 million in revenue with just five employees. These entities hold hundreds of patents and act as royalty collection hubs. They operate under a tax regime that is not only low in headline rate, but generous in its treatment of intangibles and R&D.
The Dutch funnel
Above the Irish subsidiaries sits C.P. Pharmaceuticals International C.V. (CPPI CV), a Dutch limited partnership that owns over 300 Pfizer subsidiaries, including the Irish ones.
In 2022–23, CPPI CV reported $46.9 billion in revenue and $12.97 billion in pre-tax income. It held $67 billion in intangible assets—much of it likely linked to Irish-held IP—and distributed over $20 billion in cash and dividends to Pfizer’s US and Luxembourg holding companies. Despite its scale, it reported a tax charge of just $1.58 billion, or 12.2 per cent.
CPPI CV’s hybrid legal nature—transparent for Dutch tax purposes, opaque for US ones—enables Pfizer to delay or avoid US tax on these earnings until they are formally repatriated. From the Netherlands, profits flow through Luxembourg entities such as Pfizer Holdings International Luxembourg SARL, where interest deductibility and treaty benefits further reduce tax liabilities.
Structural, not incidental
The resulting arrangement is not the product of loopholes, but of deliberate planning. Since the passage of US tax reform in 2017, Pfizer has routinely posted global tax rates in the single digits. In the United States, its effective tax rate has been negative in multiple years.
This is not simply a matter of shifting manufacturing overseas. It is about shifting profits—by locating intellectual property, and the rights to global income, in jurisdictions that offer leniency and confidentiality.
In Pfizer’s world, intellectual property is not just a scientific asset. It is a financial instrument, deployed to separate earnings from taxation. What begins in a laboratory often ends in Luxembourg.
Leave a Reply